Castle Biosciences to Acquire Previse
Deal News | May 05, 2025 | Globenewswire
Castle Biosciences, a diagnostics company, has announced a definitive agreement to acquire Previse, a firm specializing in gastrointestinal health, including technologies for chronic acid reflux-related diseases. This acquisition aims to enhance Castle's gastroenterology offerings, adding Previse's innovative methylation technology and other R&D projects. Castle Biosciences' CEO sees this as a strategic growth initiative that will complement their existing suite of diagnostics, such as the TissueCypher Barrett’s Esophagus test. Previse, bolstered by technologies developed at Johns Hopkins University, provides services that align with Castle's goal to expand early detection and improve patient outcomes in gastroenterology. This acquisition aligns with Castle’s broader focus to address unmet medical needs and provide a robust testing portfolio. The acquisition is expected to finalize soon, pending customary conditions.
Sectors
- Healthcare Technology
- Biotechnology
Geography
- United States – Both Castle Biosciences, headquartered in Friendswood, Texas, and Previse, with its technology developed in collaboration with Johns Hopkins University, are based in the U.S.
Industry
- Healthcare Technology – The article discusses Castle Biosciences and Previse's focus on innovative medical diagnostics and technologies used to improve patient care in gastrointestinal health.
- Biotechnology – Previse's development of biomarker technologies, especially those developed in collaboration with Johns Hopkins University, positions this acquisition within the biotechnology sector.
Financials
- Undisclosed – The terms of the acquisition agreement between Castle Biosciences and Previse are not disclosed.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Castle Biosciences, Inc. | Acquirer | Company | A diagnostics company focused on improving health through innovative tests, with a range of products in dermatology, gastroenterology, and mental health. |
| Previse (Capsulomics, Inc.) | Target Company | Company | A gastrointestinal health company focused on chronic acid reflux-related diseases, noted for its methylation technology developed at Johns Hopkins University. |
| Johns Hopkins University School of Medicine | Technology Provider | Institution | Provided the founding technology for Previse's biomarker and methylation research through Dr. Stephen Meltzer’s lab. |
| Derek Maetzold | CEO of Castle Biosciences | Person | President and CEO of Castle Biosciences, overseeing its strategic growth initiatives, including acquisitions. |
| Daniel Lunz | CEO of Previse | Person | Chief Executive Officer of Previse, focusing on integrating its technologies with Castle. |
| National Institutes of Health (NIH) | Funding Source | Government | Provided funding for the development of Previse's biomarker technology. |